

Press release

Zug, 8 July 2009

HBM BioVentures reduces its outstanding Going Public Convertible Bond by CHF 39 million

Going Public Convertible Bonds with a par value of CHF 39 million will be exchanged for a new bond without an equity component and with a later maturity date in order to increase financial flexibility. CHF 28 million of the new bonds have already been placed with investors.

Going Public Convertible Bonds with a par value of CHF 39 million (coupon 2.5%, maturity on 19 April 2010 at 108.6%, sec. no. 2.469.004) will be exchanged for new bonds with the same par value (coupon 10%, maturity on 16 December 2011 at 100%, sec. no. 10.265.884; "new bond"). The new bond does not contain an equity component and is to be listed on SIX Swiss Exchange. The cost of capital of the placed new bonds with a par value of CHF 28 million is slightly below 7% p.a. when considering all parameters of the transaction.

HBM BioVentures acquired Going Public Convertible Bonds with a par value of CHF 14 million on the market in April and early May 2009 at attractive prices. These Going Public Convertible Bonds will be exchanged for new bonds as part of the CHF 39 million total. Following the exchange, HBM BioVentures will sell new bonds held by itself with a par value of CHF 3 million at a price of 100%. HBM BioVentures will retain the remaining new bonds with a par value of CHF 11 million with a view to placing them on market terms. Information on the Going Public Convertible Bonds and the new bonds can be found on the company's website:

<http://www.hbmbioventures.com/en/03-investoren/wertpapiere.asp?navanchor=1010026&fileSsi=/de/03-investoren/wertpapiere.asp>.

Maturity of 2.5% HBM BioVentures Ltd Going Public Convertible Bond 2006-2010

2.5% Going Public Convertible Bonds with a par value of CHF 137 million (sec. no. 2.469.004), issued in 2006, will remain outstanding on unchanged terms. These bonds are scheduled to be redeemed on 19 April 2010 at 108.6%.

For further information, please contact Dr. Joachim Rudolf, CFO HBM BioVentures Ltd, tel.: +41 41 768 11 08, joachim.rudolf@hbmbioventures.com.

HBM BioVentures Ltd
Bundesplatz 1
CH-6300 Zug / Switzerland
Tel:+41 41 768 11 08
Fax:+41 41 768 11 09
info@hbmbioventures.com
www.hbmbioventures.com

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA



Brief profile of HBM BioVentures Ltd

HBM BioVentures is invested globally in some 40 mature emerging companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The primary products of HBM BioVentures' portfolio companies are either at an advanced stage of development or already available on the market. The company focuses on unlisted emerging companies, Two thirds of investment capital is invested in private companies with high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on the SWX Swiss Exchange (ticker: HBMN).

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM BioVentures Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM BioVentures Ltd
Bundesplatz 1
CH-6300 Zug/ Switzerland
Tel:+41 41 768 11 08
Fax:+41 41 768 11 09
info@hbmbioventures.com
www.hbmbioventures.com